Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 211 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Treatment of Sepsis Clear all

Conditions: Sepsis
Interventions: Additional physical therapy; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Clostridium Difficile Infection (CDI)
Interventions: Fidaxomicin, Vancomycin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Ypsilanti, Michigan

Conditions: Infection
Interventions: Antimicrobial Solution; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Septic Shock
Interventions: Mild Induced Hypothermia; Procedure
Lead sponsor: Danish Procalcitonin Study Group; Other
Eligibility: 50 Years to 120 Years
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sepsis, Acute Lung Injury
Interventions: Rosuvastatin, Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 745 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 40
States / cities: Fresno, California • Sacramento, California • San Francisco, California + 20 more

Conditions: Sepsis
Interventions: Code Sepsis protocol (full implementation); Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 180,402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Murray, Utah • Provo, Utah • St. George, Utah

Conditions: Infection, Hypervolemia, Hypovolemia, Septic Shock, Acute Heart Failure, Congestive Heart Failure
Interventions: Peripheral Intravenous Analysis (PIVA), Non-invasive fluid response measure, Passive leg raise (PLR); Procedure · Diagnostic Test
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts • Worcester, Massachusetts • Seattle, Washington

Conditions: Septic Shock
Interventions: Plasma, Balanced crystalloids; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sepsis, Septic Shock
Interventions: Not listed
Lead sponsor: Bluejay Diagnostics, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 5
States / cities: Gainesville, Florida • Boston, Massachusetts • Winston-Salem, North Carolina + 2 more

Conditions: Staphylococcus Aureus Bacteremia
Interventions: Ceftobiprole medocaril, Daptomycin; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more

Conditions: Septic Shock
Interventions: selepressin, placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 868 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 17
States / cities: Colorado Springs, Colorado • Idaho Falls, Idaho • Chicago, Illinois + 13 more

Conditions: Sepsis
Interventions: Vitamin C, Thiamine, Hydrocortisone, Vitamin C Placebo, Thiamine Placebo, Hydrocortisone Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 43
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more

Conditions: Septic Shock
Interventions: Early Vasopressors, Early Fluids; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 50
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 36 more

Conditions: Catheter-related Bloodstream Infection
Interventions: Chlorhexidine-impregnated foam dressing; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1,088 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Sepsis, Gastroenteritis, Dehydration
Interventions: SonoSite Maxx Series Ultrasound System; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Up to 21 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions: CF-301, Placebo; Biological · Drug
Lead sponsor: ContraFect; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more

Conditions: Catheter-Related Infections
Interventions: Mino-Lok Therapy (MLT); Drug
Lead sponsor: Leonard-Meron Biosciences, Inc.; Industry
Eligibility: 12 Years and older
U.S. locations: 27
States / cities: Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 21 more

Conditions: Severe Sepsis
Interventions: Zinc sulfate; Dietary Supplement
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Septic Shock
Interventions: Hydrocortisone, sodium succinate, Normal saline; Drug
Lead sponsor: Jerry Zimmerman; Other
Eligibility: 1 Month to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 18
States / cities: Tucson, Arizona • Los Angeles, California • Oakland, California + 15 more

Conditions: Systemic Inflammatory Response Syndrome
Interventions: Azithromycin on admission - not enrolled in the RCT; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Interventions: Best Practice, Biospecimen Collection, Cytarabine, Electronic Health Record Review, Placebo Administration, Xylitol-containing Oral Wipe; Other · Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 25 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 39
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Madera, California + 35 more

Conditions: Severe Sepsis
Interventions: Drotrecogin alfa (activated); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 17
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fresno, California + 14 more

Conditions: Sepsis
Interventions: personalized dosing adjustment of vancomycin; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Sepsis Trial of Early Physical Therapy Outside the ICU

A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections

Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)

The Cooling And Surviving Septic Shock Study (CASS)

Statins for Acutely Injured Lungs From Sepsis

Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care

Observational Study to Evaluate Peripheral IntraVenous Analysis (PIVA) in Euvolemic, Hypovolemic, and Hypervolemic Emergency Department Patients

Resuscitation With Plasma in Surgical and Trauma Patients With Septic Shock

Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Vitamin C, Thiamine, and Steroids in Sepsis

Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis

Reducing Catheter-Related Bloodstream Infections in the ICU With a Chlorhexidine-Impregnated Sponge (BIOPATCH)

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

Zinc Therapy in Critical Illness

Stress Hydrocortisone In Pediatric Septic Shock

Efficacy of Macrolide Immunomodulation in Severe Sepsis.

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention